Cardiac Uptake of Metformin, Visualized by Positron Emission Tomography

Henrik Wiggers6 enrolled

Overview

The purpose of the study is to evaluate if metformin is taken up into the failing myocardium. Recent experimental and epidemiological studies have shown beneficial effects of metformin on heart failure. It is unknown whether this effect is direct or indirect. The aim of the study is to investigate if metformin is taken up in heart failure using a novel 11C-metformin tracer and positron emission tomography (PET).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Heart Failure, Systolic

Interventions

11C-metforminRADIATION

200 MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Positron Emission Tomography

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with chronic heart failure, Left Ventricular Ejection Fraction \<45% * New York Heart Association (NYHA) class I, II, III * Relatively preserved renal function (eGFR \> 30 ml/min) * Ability to understand the written patient information and to give informed consent * Negative p-HCG for women of childbearing potential Exclusion Criteria: * Known allergy to metformin * Age \< 18 years * Current abuse of alcohol or drugs

Locations (1)

Aarhus University Hospital, Department of Cardiology, Palle Juul-Jensens Boulevard 99

Aarhus N, Denmark

Outcomes

Primary Outcomes

Metformin uptake in the failing myocardium

Cardiac uptake is evaluated through analysis of acquired PET-images.

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.